Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 4,201–4,300 of 10,906
Tsourdi, E. A., Yu, E. W.-Y., de Beur, S. M. J., & Drake, M. T. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4304 · Cited by 18
Doneddu, P. E., Spina, E., Briani, C., Fabrizi, G. M., Manganelli, F., & Nobile‐Orazio, E. (2021) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12435 · Cited by 16
Mokuda, S., Watanabe, H., Kohno, H., Ishitoku, M., Araki, K., Hirata, S., & Sugiyama, E. (2022) · Cytotechnology · doi:10.1007/s10616-022-00540-4 · Cited by 17
Truong, L. B., Medina-Cruz, D., & Mostafavi, E. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125185 · Cited by 18
Guo, X., Liu, D., Huang, Y., Deng, Y., Wang, Y., Mao, J., Zhou, Y., Xiong, Y., & Gao, X. (2023) · Virology Journal · doi:10.1186/s12985-023-02023-0 · Cited by 20
Nucleic acid vaccines and CpG oligodeoxynucleotides for allergen immunotherapy
Jacquet, A. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000772 · Cited by 15
Dan, J. M., Antunes, R. D. S., Grifoni, A., Weiskopf, D., Crotty, S., & Sette, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac310 · Cited by 17
General Independent Censoring in Event-Driven Trials with Staggered Entry
Rühl, J., Beyersmann, J., & Friedrich, S. (2022) · Biometrics · doi:10.1111/biom.13710 · Cited by 20
Peptides and peptidomimetics as therapeutic agents for Covid‐19
Dahal, A., Sonju, J. J., Kousoulas, K. G., & Jois, S. D. S. (2021) · Peptide Science · doi:10.1002/pep2.24245 · Cited by 17
Post COVID-19 vaccine deaths - Singapore’s early experience
Yeo, A., Kuek, B., Mandy, L. A. U., Tan, S. R., & Chan, S. (2022) · Forensic Science International · doi:10.1016/j.forsciint.2022.111199 · Cited by 18
Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Schmidt, A. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.539332 · Cited by 15
Golshani, M., & Hrdý, J. (2022) · Vaccines · doi:10.3390/vaccines10020279 · Cited by 16
Deciphering Fc-effector functions against SARS-CoV-2
Beaudoin-Bussières, G., & Finzi, A. (2024) · Trends in Microbiology · doi:10.1016/j.tim.2024.01.005 · Cited by 19
Sarin, K. Y., Zheng, H., Chaichian, Y., Arunachalam, P. S., Swaminathan, G., Eschholz, A., Gao, F., Wirz, O. F., Lam, B. K., Yang, E., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.176556 · Cited by 16
Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics
Roland, L. T., Regenberg, A. C., Luong, A., Wise, S. K., Toskala, E. M., Lam, K. K., Levy, J. M., Franzese, C. B., Smith, K. A., & Kim, J. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22864 · Cited by 16
Niessen, F. A., Knol, M. J., Hahné, S. J. M., Bonten, M. J. M., & Bruijning-Verhagen, P. C. J. L. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.011 · Cited by 15
“Disease severity endpoints Days in hospital (median [IQR]) 6 [6,7] 6 [3,9] 6 [3,10]”
Vaccination against SARS‐CoV‐2 and psoriasis: the three things every dermatologist should know
Diotallevi, F., Campanati, A., Radi, G., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17256 · Cited by 15
The Impact of the Global COVID-19 Vaccination Campaign on All-Cause Mortality
Agrawal, V., Sood, N., & Whaley, C. (2023) · National Bureau of Economic Research · doi:10.3386/w31812 · Cited by 20
Challenges in Emerging Vaccines and Future Promising Candidates against SARS‐CoV‐2 Variants
Ghildiyal, T., Rai, N., Rawat, J. M., Singh, M., Anand, J., Pant, G., Kumar, G., & Shidiki, A. (2024) · Journal of Immunology Research · doi:10.1155/2024/9125398 · Cited by 18
Delivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy
Padmaswari, M. H., Agrawal, S., Jia, M. S., Ivy, A., Maxenberger, D. A., Burcham, L. A., & Nelson, C. E. (2023) · Biophysics Reviews · doi:10.1063/5.0131452 · Cited by 19
Severe Relapsed Autoimmune Hemolytic Anemia after Booster with mRNA-1273 COVID-19 vaccine
Mesina, F. Z. (2022) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2022.05.001 · Cited by 15
Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen
Fazli, S., Thomas, A., Estrada, A. E., Ross, H. A. P., Lee, D. X., Kazmierczak, S. C., Slifka, M. K., Montefiori, D. C., Messer, W. B., & Curlin, M. E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176411 · Cited by 17
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
Rieckmann, P., Centonze, D., Giovannoni, G., Hua, L. H., Oreja‐Guevara, C., Selchen, D. H., Sørensen, P. S., Vermersch, P., Wiendl, H., Salloukh, H., et al. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211058298 · Cited by 15
Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease
Kastl, A., Weaver, K. N., Zhang, X., Strople, J. A., Adler, J., Dubinsky, M. C., Bousvaros, A., Watkins, R. D., Dai, X., Chen, W., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002016 · Cited by 15
Liu, J., Mao, Q., Wu, X., He, Q., Bian, L., Bai, Y., Wang, Z., Wang, Q., Zhang, J., Liang, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.814365 · Cited by 17
Na, Y. S., Kim, J. H., Baek, M. S., Kim, W., Baek, A.-R., Lee, B. Y., Seong, G. M., & Lee, S. (2022) · Acute and Critical Care · doi:10.4266/acc.2022.00017 · Cited by 16
Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
Vietri, M., D'Elia, G., Caliendo, G., Passariello, L., Albanese, L., Molinari, A., & Angelillo, I. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.045 · Cited by 15
Stroke After SARS-CoV-2 mRNA Vaccine: A Nationwide Registry Study
Ihle‐Hansen, H., Bøås, H., Tapia, G., Hagberg, G., Ihle‐Hansen, H., Berild, J. D., Selmer, R. M., Karlstad, Ø., Gulseth, H. L., & Ariansen, I. (2023) · Stroke · doi:10.1161/strokeaha.122.040430 · Cited by 17
Zou, Y., Lu, J., Lian, Z., Jia, J., Shen, J., Li, Q., Wong, J. M. J., Jin, K., Yan, W., Ren, X.-Y., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072340 · Cited by 17
“24 Despite concerns of fast degradation, intradermal naked mRNA injection effectively elicited immunogenicity.”
Early antibody responses associated with survival in COVID19 patients
Zhou, Z., Dharmarajan, S. H., Lehtimaki, M., Kirshner, S., & Kozlowski, S. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009766 · Cited by 17
Tong, D., Zhang, M., Yang, Y., Xia, H., Tong, H., Zhang, H., Zeng, W., Liu, M., Wu, Y. L., Ma, H., et al. (2022) · Protein & Cell · doi:10.1093/procel/pwac020 · Cited by 15
Álvarez, M. M., Bravo-González, S., & Santiago, G. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254430 · Cited by 15
Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina
Uschner, D., Bott, M., Santacatterina, M., Gunaratne, M., Fette, L. M., Burke, B., Strylewicz, G., Edelstein, S. L., Lagarde, W. H., MILLER, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10111922 · Cited by 19
Executable network of SARS-CoV-2-host interaction predicts drug combination treatments
Howell, R. S. M., Clarke, M. A., Reuschl, A., Chen, T., Abbott-Imboden, S., Singer, M., Lowe, D. M., Bennett, C. L., Chain, B., Jolly, C. L., et al. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00561-5 · Cited by 18
Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction
Marabotti, C. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2067531 · Cited by 13
“0 119 (Pfizer-BioNtech) mRNA1273 [4] 1.”
Leomanni, L., Collatuzzo, G., Sansone, E., Sala, E., Palma, G. D., Porru, S., Spiteri, G., Monaco, M. G. L., Basso, D., Pavanello, S., et al. (2023) · Vaccines · doi:10.3390/vaccines11101527 · Cited by 17
Why Molnupiravir Fails in Hospitalized Patients
Brown, A. N., Lang, Y., Zhou, J., Franco, E. J., Hanrahan, K. C., Bulitta, J. B., & Drusano, G. L. (2022) · mBio · doi:10.1128/mbio.02916-22 · Cited by 17
Meerasa, S. S., Ahmad, A., Khan, A. A., Haque, S., & Saleem, I. Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126263 · Cited by 15
Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities
Liu, S., Kang, M., Zhao, N., Zhuang, Y., Li, S., & Song, T. (2022) · Medical Review · doi:10.1515/mr-2021-0021 · Cited by 15
Correlates of Covid-19 Vaccine Acceptance among Residents of Ohio: A Cross-sectional Study
Haile, Z. T., Ruhil, A. V. S., Bates, B. R., van Hall, O., & Grijalva, M. J. (2022) · BMC Public Health · doi:10.1186/s12889-022-12661-8 · Cited by 16
Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19
Heldman, M. R., Kates, O. S., Safa, K., Kotton, C. N., Multani, A., Georgia, S. J., Steinbrink, J. M., Alexander, B. D., Blumberg, E. A., Haydel, B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac159 · Cited by 16
Explaining higher Covid-19 vaccination among some US primary care professionals
Huang, Q. E., Gilkey, M. B., Thompson, P., Grabert, B. K., Dailey, S. A., & Brewer, N. T. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.114935 · Cited by 16
Amodio, E., Vella, G., Restivo, V., Casuccio, A., Vitale, F. M., & On Behalf Of The Covid-Surveillance Working Group Of The University Of Palermo (2022) · Vaccines · doi:10.3390/vaccines10030426 · Cited by 14
Itamochi, M., Yazawa, S., Inasaki, N., Saga, Y., Yamazaki, E., Shimada, T., Tamura, K., Maenishi, E., Isobe, J., Nakamura, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.068 · Cited by 15
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity
Roederer, A. L., Cao, Y., Denis, K. S., Sheehan, M. L., Li, C. J., Lam, E. C., Gregory, D. J., Poznansky, M. C., Iafrate, A. J., Canaday, D. H., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101850 · Cited by 26
Chen, C., Fu, F., Ding, L., Fang, J., & Xiao, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938322 · Cited by 17
Cocchio, S., Zabeo, F., Facchin, G., Piva, N., Furlan, P., Nicoletti, M., Saïa, M., Tonon, M., Mongillo, M., Russo, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10010107 · Cited by 14
Kuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Bohehm, L., Raviv, Y., Shemer-Avni, Y., Rosenberg, E., & Taube, R. (2021) · medRxiv · doi:10.1101/2021.02.22.21252002 · Cited by 17
Trigueros, M., Pradenas, E., Palacín, D., Muñoz-López, F., Ávila‐Nieto, C., Trinité, B., Bonet, J. M., Isnard, M., Moreno, N., Marfil, S., et al. (2022) · Age and Ageing · doi:10.1093/ageing/afac101 · Cited by 16
Almeida, N. D., Schiller, I., Ke, D., Sakr, E., Plesa, M., Vanamala, S., Moneger, A.-L., Bazan, M., Lucchesi, C., Woźniak, N. J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330549 · Cited by 16
Aabakken, L., Ebigbo, A., Antonelli, G., et al. (2021) · Endoscopy International Open · doi:10.1055/a-1400-9135 · Cited by 14
SARS‐CoV‐2 infection after two doses of mRNA vaccine in renal transplant recipients
Bašić‐Jukić, N., & Jelicić, I. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13628 · Cited by 14
Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review
Sanyaolu, A. O., Okorie, C., Marinkovic, A., Prakash, S., Williams, M., Haider, N., Mangat, J., Hosein, Z., Balendra, V., Abbasi, A. F., et al. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221097559 · Cited by 16
Voices of Undergraduate Students With Disabilities During the COVID-19 Pandemic: A Pilot Study
Kourea, L., Christodoulidou, P., & Fella, A. (2021) · European Journal of Psychology Open · doi:10.1024/2673-8627/a000011 · Cited by 25
Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine
McMillan, C. L. D., Choo, J. J., Idris, A., Supramaniam, A., Modhiran, N., Amarilla, A., Isaacs, A., Cheung, S. T. M., Liang, B., Bielefeldt-Ohmann, H., et al. (2021) · bioRxiv · doi:10.1101/2021.05.30.446357 · Cited by 45
Luangdilok, S., Wanchaijiraboon, P., Pakvisal, N., Susiriwatananont, T., Zungsontiporn, N., Sriuranpong, V., Sainamthip, P., Suntronwong, N., Vichaiwattana, P., Wanlapakorn, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10101613 · Cited by 13
COVID-19 and severity of liver diseases: Possible crosstalk and clinical implications
Imam, M. T., Almalki, Z. S., Alzahrani, A. R., Al-Ghamdi, S. S., Falemban, A. H., Alanazi, I. M., Shahzad, N., Alrooqi, M. M., Jabeen, Q., & Shahid, I. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110439 · Cited by 15
Ito, Y., Honda, A., & Kurokawa, M. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.03.012 · Cited by 15
Safe Surgery During the COVID-19 Pandemic
Singhal, R., Dickerson, L., Sakran, N., Pouwels, S., Chiappetta, S., Weiner, S. R., Purkayastha, S., Madhok, B., & Mahawar, K. K. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00458-6 · Cited by 18
Covid-19 vaccine immunogenicity in people living with HIV-1
(2021) · doi:10.1101/2021.08.13.456258 · Cited by 14
Goethem, N. V., Serrien, B., Vandromme, M., Wyndham-Thomas, C., Catteau, L., Brondeel, R., Klamer, S., Meurisse, M., Cuypers, L., André, E., et al. (2021) · Archives of Public Health · doi:10.1186/s13690-021-00709-x · Cited by 17
Dual targeted lipid nanoparticles for enhanced DNA delivery and transfection of breast cancer cells
Lotter, C., Stierli, M. A., Puligilla, R. D., & Huwyler, J. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114674 · Cited by 16
Involvement of the STING signaling in COVID-19
Xiao, R., & Zhang, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006395 · Cited by 15
Fernández‐Lázaro, D., Fernandez-Lazaro, C. I., Mielgo‐Ayuso, J., Adams, D. P., García, J. L., Gonzalez-Bernal, J. J., & González‐Gross, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698672 · Cited by 17
Message in a bottle: mRNA vaccination for influenza
Shartouny, J. R., & Lowen, A. C. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001765 · Cited by 17
Nie, X., Liu, Y., Song, Y., Yao, X., Chen, Y., Lee, H., & Gao, X. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady6730 · Cited by 23
Estimation of Relative Vaccine Effectiveness in Influenza: A Systematic Review of Methodology
McMenamin, M. E., Bond, H. S., Sullivan, S. G., & Cowling, B. J. (2022) · Epidemiology · doi:10.1097/ede.0000000000001473 · Cited by 18
Advancing vaccine technology through the manipulation of pathogenic and commensal bacteria
Lloren, K. K. S., Senevirathne, A., & Lee, J. H. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101349 · Cited by 21
Graves’ disease after COVID-19 vaccination
Chua, M. W. J. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021398 · Cited by 14
Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19
Castro, A. D., Mayr, F., Talisa, V. B., Shaikh, O. S., Omer, S. B., Yende, S. P., & Butt, A. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.38507 · Cited by 14
Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report
Šín, R., & Struncova, D. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i24.7218 · Cited by 14
Warpechowski, J. J., Leszczyńska, P., Juchnicka, D., Olichwier, A. J., Szczerbiński, Ł., & Kretowski, A. J. (2023) · Vaccines · doi:10.3390/vaccines11071203 · Cited by 21
Ferreira, F. D. Q. T., Araújo, D. C., de Albuquerque, L. M., Bianchini, P. M., de Holanda, E. C., & Pugliesi, A. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2093756 · Cited by 13
Marra, A. R., Miraglia, J. L., Malheiros, D. T., Guozhang, Y., Teich, V., Victor, E. D. S., Pinho, J. R. R., Cypriano, A. S., Vieira, L. W., Polonio, M., et al. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.50 · Cited by 14
Factors associated with stroke after COVID-19 vaccination: a statewide analysis
Nahab, F. B., Bayakly, R. A., Sexton, M. E., Lemuel-Clarke, M., Henríquez, L., Rangaraju, S., & Ido, M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1199745 · Cited by 17
Riddler, S. A., Moodie, Z., Clark, J. L., Yen, C., Allen, M., Furch, B. D., Lu, H., Grant, S., Mondal, K., Anderson, M., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02701 · Cited by 18
Self-citationFalahi, S., Sayyadi, H., & Kenarkoohi, A. (2022) · Health Science Reports · doi:10.1002/hsr2.874 · Cited by 14
Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination
Sekulovski, M., Mileva, N. B., Vasilev, G., Miteva, D., Gulinac, M., Peshevska-Sekulovska, M., Chervenkov, L., Batselova, H., Vasilev, G., Tomov, L., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102813 · Cited by 15
Meena, J., Singhvi, P., Srichandan, S., Dandotiya, J., Verma, J., Singh, M., Ahuja, R., Panwar, N., Wani, T. Q., Khatri, R., et al. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.05.008 · Cited by 14
Lü, Y. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003697 · Cited by 14
mRNA biotherapeutics landscape for rare genetic disorders
Iyer, V. R., Praveen Reddy., P., Kaduskar, B., Moharir, S. C., & Mishra, R. K. (2024) · Journal of Biosciences · doi:10.1007/s12038-023-00415-6 · Cited by 19
Bohnert, A. S. B., Kumbier, K. E., Rowneki, M., Gupta, A. B., Bajema, K. L., Hynes, D. M., Viglianti, E. M., O’Hare, A. M., Osborne, T. F., Boyko, E. J., et al. (2023) · BMJ · doi:10.1136/bmj-2022-074521 · Cited by 15
Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies
Huang, X., Liang, X., Zhang, J., Su, H., & Chen, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11143968 · Cited by 15
Exploration of mRNA nanoparticles based on DOTAP through optimization of the helper lipids
Ma, X., Wu, F., Peng, C., Chen, H., Zhang, D., & Han, T. (2023) · Biotechnology Journal · doi:10.1002/biot.202300123 · Cited by 18
The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
Wang, J., Zhang, Q., Wang, H., & Gong, W. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705157 · Cited by 15
Araste, F., Bakker, A. D., & Zandieh‐Doulabi, B. (2023) · Journal of Nanoparticle Research · doi:10.1007/s11051-023-05867-3 · Cited by 18
Erythema Migrans-like COVID Vaccine Arm: A Literature Review
Fasano, G., Bennardo, L., Ruffolo, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030797 · Cited by 14
Work Absence Following COVID-19 Vaccination in a Cohort of Healthcare Personnel
Breeher, L. E., Wolf, M. E., Geyer, H. L., Brinker, T., Tommaso, C., Kohlnhofer, S., Hainy, C., & Swift, M. D. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002376 · Cited by 14
Kulikowski, C. A. (2021) · Yearbook of Medical Informatics · doi:10.1055/s-0041-1726482 · Cited by 15
COVID-19 vaccines: A perspective from social pharmacology
Montastruc, J., Lafaurie, M., de Canecaude, C., Montastruc, F., Bagheri, H., Durrieu, G., & Sommet, A. (2021) · Therapies · doi:10.1016/j.therap.2021.05.010 · Cited by 15
Petrie, J. G., King, J. P., McClure, D. L., Rolfes, M. A. R., Meece, J. K., Pattinson, D., Neumann, G., Kawaoka, Y., Belongia, E. A., & McLean, H. Q. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13104 · Cited by 16
Hedges, J. F., Thompson, M. A., Snyder, D. T., Robison, A., Taylor, M. P., & Jutila, M. A. (2021) · Vaccines · doi:10.3390/vaccines9060587 · Cited by 14
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.